James P. Brady
Human Resources Officer bei SPERO THERAPEUTICS, INC.
Profil
James P.
Brady is currently the Chief Human Resource Officer at Spero Therapeutics, Inc. Previously, he held the position of Vice President-Human Resources at Intarcia Therapeutics, Inc. and was the Chief Human Resources Officer at uniQure NV.
He received a graduate degree from Harvard University and an undergraduate degree from Marietta College.
Aktive Positionen von James P. Brady
Unternehmen | Position | Beginn |
---|---|---|
SPERO THERAPEUTICS, INC. | Human Resources Officer | - |
Ehemalige bekannte Positionen von James P. Brady
Unternehmen | Position | Ende |
---|---|---|
UNIQURE N.V. | Human Resources Officer | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Human Resources Officer | - |
Ausbildung von James P. Brady
Harvard University | Graduate Degree |
Marietta College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |